- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 19, 2017 P2, N=0, Withdrawn, N=23 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2018 --> May 2017
|